Secondary Logo

Institutional members access full text with Ovid®

Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy

Brinton, Louise A., PhD1; Brogan, Donna R., PhD2; Coates, Ralph J., PhD3; Swanson, Christine A., PhD4; Potischman, Nancy, PhD4; Stanford, Janet L., PhD5

doi: 10.1097/GME.0000000000001217
Commemorative Papers
Buy

Objective: To assess effects on breast cancer risk of exposure to both oral contraceptives and menopausal hormones, an increasingly common exposure.

Design: A case-control study of breast cancer among women under the age of 55 years in Atlanta, GA involving 1,031 cases and 919 population controls was conducted.

Results: Ever use of oral contraceptives was associated with a relative risk of 1.1 (95% 0.9-1.4), whereas the relative risk for hormone replacement therapy was 0.9 (95% CI 0.7-1.2). Seventeen percent of the cases versus 19% of the population controls reported exposure to both agents, resulting in a relative risk of 1.0 (95% CI 0.7-1.4) relative to those unexposed to either preparation. Although there was little variation in risk associated with joint effects by either age or race, there were statistically nonsignificant elevations in risk for this exposure among women who had experienced a natural menopause (relative risk = 2.0, 95% CI 0.7-5.6), were relatively thin (relative risk = 1.5, 0.8-3.0), or who had a first degree relative with breast cancer (relative risk = 2.0, 0.6-7.0). When joint effects of longer term use of both agents were considered, subjects who reported use of oral contraceptives for 10 or more years and hormone replacement for 3 or more years had a relative risk of 3.2 (95% CI 1.4-7.4) compared with nonusers of either preparation.

Conclusions: Although our results must be cautiously interpreted given small numbers within subgroups, they raise concern and emphasize the need for further evaluation on breast cancer risk of the increasingly common exposure to both oral contraceptives and hormone replacement therapy.

1Environmental Epidemiology Branch

2Rollins School of Public Health, Emory University, Atlanta, Georgia

3Centers for Disease Control and Prevention, Atlanta, Georgia

4Nutritional Epidemiology Branch, National Cancer Institute, Bethesda, Maryland

5Fred Hutchinson Cancer Research Center, Seattle, Washington.

Address correspondence to: Dr. Louise A. Brinton, PhD, National Cancer Institute, Executive Plaza North Room 443, 6130 Executive Boulevard MSC 7374, Bethesda, Maryland 20892-7374, USA.

Received 18 February, 1998

Revised 19 May, 1998

Accepted 19 May, 1998

Menopause 1998;5:145-151. Reprinted with permission.

© 2018 by The North American Menopause Society.